Who Should Be Monitored for Tysabri-Related PML?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational Exposure Concerns

If you or a loved one has taken Tysabri, you may wonder about the risk of progressive multifocal leukoencephalopathy (PML). The medical community has long recognized that certain patient histories—such as longer treatment duration or prior immunosuppressant use—increase the need for vigilance. This page reviews the clinical red flags that guide monitoring decisions.

Tysabri Pharmacology and PML Risk: A Bridge from Occupational Exposure to Clinical Evidence

Building on the need for occupational vigilance, it is essential to examine the specific clinical evidence regarding Tysabri (natalizumab) and its association with progressive multifocal leukoencephalopathy (PML). Tysabri is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of PML, a severe opportunistic brain infection caused by the JC virus. The following narrative synthesizes evidence from FDA-approved labeling and clinical data to describe the medical facts, risk factors, and settlement-related considerations for affected patients. Tysabri is a monoclonal antibody that binds to alpha-4 integrin, preventing immune cell migration into the central nervous system. This mechanism reduces inflammation in multiple sclerosis but also impairs immune surveillance against JC virus, allowing reactivation and PML development. In clinical trials, PML occurred in three patients who received Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Two cases were observed among 1869 multiple sclerosis patients treated for a median of 120 weeks; these patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1043 Crohn's disease patients evaluated for PML. Common adverse reactions include headache, influenza-like illness, peripheral edema, and infections such as sinusitis and urinary tract infections.

Clinical Presentation and Diagnosis of PML

PML is an opportunistic viral infection of the brain caused by the JC virus, which typically only occurs in immunocompromised individuals. The condition usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation varies but commonly includes progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. Early recognition is critical because prompt intervention may improve outcomes, though the prognosis remains poor.

Mechanistic Pathways and Risk Factors for Tysabri-Associated PML

The primary mechanism involves Tysabri's inhibition of lymphocyte trafficking into the brain. This reduces the normal immune surveillance that keeps JC virus in check. Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additional risk factors include longer treatment duration, especially beyond two years, and prior use of immunosuppressants. These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Settlement Considerations

The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning specifies risk factors: presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, some patients have developed PML, raising questions about whether the warnings were sufficient to allow informed decision-making. Patients who develop PML after Tysabri therapy may pursue legal claims based on inadequate warnings or failure to adequately monitor. Settlement criteria typically consider the presence of anti-JCV antibodies, duration of Tysabri use, prior immunosuppressant exposure, and the timing of diagnosis. The severity of PML—often leading to death or severe disability—is a central factor in settlement valuation. Evidence from clinical trials shows that PML occurred in patients treated for a median of 120 weeks in multiple sclerosis and after eight doses in Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This timeline is important for establishing causation and determining whether monitoring protocols were followed.

Timeline Between Exposure and Documented Harm

In clinical trials, PML developed after varying durations of Tysabri exposure. For multiple sclerosis patients, the two cases occurred after a median treatment duration of 120 weeks (approximately 2.3 years). The Crohn's disease patient developed PML after eight doses, which corresponds to roughly 8 months of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability underscores the importance of continuous monitoring throughout treatment. The boxed warning advises withholding Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Delays in diagnosis can worsen outcomes, making timely recognition essential.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how does it cause PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It works by blocking immune cell entry into the brain, which can allow the JC virus to reactivate and cause progressive multifocal leukoencephalopathy (PML), a severe brain infection. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)

What are the risk factors for developing PML while on Tysabri?

Risk factors include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)

What settlement criteria are considered for Tysabri-related PML claims?

Settlement criteria typically include the presence of anti-JCV antibodies, duration of Tysabri use, prior immunosuppressant exposure, timing of diagnosis, and severity of PML. Evidence from clinical trials shows PML occurred after a median of 120 weeks in MS patients and after eight doses in Crohn's disease patients. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Tysabri Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.